What Happens When You Stop Tirzepatide? What the Trials Actually Show
This is the question people ask quietly, usually after they have already started. The answer is well documented, it is not comfortable, and knowing it before you begin is far more useful than finding out afterwards.
The short answer
Weight tends to come back. In the SURMOUNT-4 trial, people who stopped tirzepatide regained 14.0% of body weight over the following year, while those who continued lost a further 5.5%. They still ended up meaningfully lighter than at the start, but most of what they had lost returned. This is the medication effect ending, not a personal failure.
What the tirzepatide withdrawal trial found
There is a trial designed specifically to answer this question, which is unusual and worth knowing about. SURMOUNT-4, published in JAMA in January 2024, was a randomised withdrawal study across 70 sites in four countries.
The design is what makes it useful. Everyone started on the same footing:
- 783 adults entered a 36-week open-label lead-in, taking the maximum tolerated dose of tirzepatide, 10 or 15 mg weekly
- By week 36, the 670 who completed it had lost 20.9% of their body weight on average
- They were then randomly split: half continued tirzepatide, half switched to placebo, for 52 more weeks
Neither group knew which they were on. Both continued with diet and physical activity guidance. The only variable was the medication.
| Continued tirzepatide | Switched to placebo | |
|---|---|---|
| Weight change, week 36 to 88 | Lost a further 5.5% | Regained 14.0% |
| Kept at least 80% of the weight lost | 89.5% of participants | 16.6% of participants |
| Total change from week 0 to 88 | 25.3% below starting weight | 9.9% below starting weight |
Two things in that table deserve to be read carefully, because they usually get reported as only one.
The regain is real and substantial. A 19.4 percentage point gap opened up between the two groups in a year. Fewer than one in six people who stopped held onto most of their loss, against nearly nine in ten who continued.
But stopping did not put people back where they started. The placebo group finished the full 88 weeks still 9.9% below their starting weight. That is not nothing, and it is a detail worth holding onto if you are weighing this up, because the headlines tend to imply a total reversal that the data does not show.
The same pattern with semaglutide
This is not specific to tirzepatide. The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, followed participants for a year after semaglutide was withdrawn and found they regained about two-thirds of their prior weight loss within that year.
That study added a finding the tirzepatide trial frames slightly differently, and it is arguably the more important one: the cardiometabolic improvements moved back along with the weight.
Most people do not want a GLP-1 for the number on the scale. They want it for what the weight loss does to blood pressure, blood sugar, lipids and long-term risk. The STEP 1 extension suggests those benefits are tied to maintaining the result rather than to having reached it once.
Why does this happen?
The mechanism is not mysterious, and understanding it takes the shame out of it.
GLP-1 medications work while they are present, by changing appetite signalling and how full you feel after eating. They are not retraining your body to permanently need less food. When the drug clears, that signalling returns to roughly where it was.
On top of that, the body actively defends a weight it has held for a long time, through hormonal and metabolic adjustments that push toward regain. Losing weight does not switch that off. It is arguably the central difficulty of obesity treatment in general, and it predates these medications entirely.
The closest everyday comparison is blood pressure medication. Stopping it returns blood pressure to where it was. Nobody calls that a treatment failure, because everyone understands it is managing an ongoing condition rather than curing one. GLP-1 medication for weight is increasingly understood the same way, and the SURMOUNT-4 authors framed their conclusion in exactly those terms: withdrawal led to substantial regain, continued treatment maintained and extended the result.
What actually helps you keep it off
Being straight about the limits here: there is no trial-proven protocol for maintaining weight loss after stopping a GLP-1. Anyone presenting a guaranteed method is ahead of the evidence. What follows is the reasonable reading of what the trials show, not a promise.
Build the habits while the medication is still working
Appetite suppression is a window, not just a result. Eating patterns and a training routine are far easier to establish while hunger is reduced than to construct from scratch after it returns. Treating the medicated phase as the easy period in which to build habits, rather than the period in which nothing else is required, is the single most sensible reading of the data.
Protect lean mass on the way down
Muscle is metabolically active tissue. Losing a large share of it during the loss phase leaves you with a lower daily energy expenditure to defend the result afterwards, which makes regain easier. This is one of the practical arguments for paying attention to protein, resistance training and body composition while you are still losing, and we cover it fully in our guide on how to keep muscle on a GLP-1.
Make stopping a clinical decision, not a default
People come off these medications for real reasons: cost, side effects, supply problems, life changes. The trial data does not argue that nobody should ever stop. It argues that the decision has a predictable consequence, so it is better planned with a clinician, including whether a taper or a maintenance dose makes sense for you, than drifted into.
Check what your provider does after the prescription ends
This is the practical question most people never think to ask before enrolling, and it is genuinely where telehealth providers differ. Some programs are structured entirely around the active prescription and contact effectively ends with it.
Worth asking before you sign up anywhere
Ask what happens to your plan and support when you come off the medication, whether post-medication guidance is included, and whether tapering is managed clinically. Of the providers we have reviewed, HumeCare+ lists post-medication guidance as part of the plan, and tracks body composition throughout so the lean mass question is visible rather than assumed. Our review covers what it includes, what it costs, and what its money-back promise actually covers.
Read the full HumeCare+ reviewIf you have already stopped and the weight is coming back
Two things are worth saying plainly.
You did not do anything wrong. In SURMOUNT-4 the regain happened in a controlled trial, to people receiving diet and activity guidance, monitored throughout. It is a pharmacological effect ending, and it happened to more than 83% of the placebo group.
You are probably not back at square one. The average participant who stopped still finished nearly 10% below their starting weight after a full year off treatment. Whatever has come back, the picture is usually not the total reversal it can feel like from the inside.
What to do next is a clinical conversation rather than an internet one, and the options genuinely exist, including restarting, a maintenance dose, or a different approach entirely.
This article is general information, not medical advice. Never start, stop, taper or change the dose of a prescription medication based on something you read online. Those decisions belong with the clinician who knows your history.
Frequently asked questions
What happens when you stop tirzepatide?
Appetite returns and weight tends to come back. In the SURMOUNT-4 trial, published in JAMA in 2024, participants who had lost an average of 20.9% of their body weight over 36 weeks were then randomly assigned to continue tirzepatide or switch to placebo. Over the following 52 weeks the placebo group regained 14.0% of their body weight, while those who continued lost a further 5.5%. This is a medication effect ending, not a personal failure.
Do you regain all the weight after stopping tirzepatide?
Not all of it, on average, but a substantial share. In SURMOUNT-4, the group that switched to placebo still ended the full 88-week study 9.9% below where they started, compared with 25.3% for those who stayed on treatment. So meaningful weight loss was retained overall, but most of what was regained came back within a year. Only 16.6% of the placebo group held onto at least 80% of their original loss, against 89.5% of those who continued.
How quickly do you regain weight after stopping a GLP-1?
The trial data measures this over roughly a year rather than week by week. SURMOUNT-4 tracked 52 weeks after withdrawal, and the STEP 1 trial extension followed participants for a year after stopping semaglutide, finding they regained about two-thirds of their prior weight loss in that time. Individual experience varies, but the pattern in both trials is a steady return over months rather than an overnight rebound.
Why do you regain weight after stopping tirzepatide?
Because the medication is treating an ongoing condition rather than curing it. GLP-1 medications work by changing appetite signalling and how full you feel. When the drug clears, that signalling returns to where it was, and the body's tendency to defend its previous weight, which does not disappear because you lost weight, reasserts itself. The same logic applies to blood pressure medication: stopping it returns blood pressure, not because the treatment failed but because it was managing something continuous.
Do the health benefits reverse too, or just the weight?
The STEP 1 trial extension found that cardiometabolic improvements largely tracked the weight back in the same direction after semaglutide was stopped. That is an important detail, because it means the benefits people most want from treatment, the changes in metabolic markers rather than the number on the scale, are tied to maintaining the result rather than to having achieved it once.
How do you keep the weight off after stopping a GLP-1?
There is no trial-proven protocol for this, and anyone selling you one is ahead of the evidence. What the data does support: the trials show that continued treatment maintains the result, so the decision to stop is worth planning with a clinician rather than defaulting into. Practically, protecting lean mass during the loss phase, building eating and training habits while appetite is still suppressed rather than after, and tapering as a clinical decision rather than an abrupt stop are the levers people actually have.
Is stopping a GLP-1 the same as failing?
No, and the framing matters because it drives people to stop quietly and feel ashamed when weight returns. The trial evidence describes a pharmacological effect that ends when the drug does, in people who did nothing wrong. Cost, side effects, supply and life circumstances are all real reasons people stop. What the data argues for is making it a planned clinical conversation instead of an unplanned one.
Should you stay on a GLP-1 forever?
That is a decision for you and a clinician, not something a website can answer, and it depends on your health situation, response, tolerance and cost. What the evidence establishes is only the trade-off: SURMOUNT-4 showed continued treatment maintained and extended the result while withdrawal reversed much of it. Knowing that trade-off before you start is more useful than discovering it after.
What should you ask a provider about stopping before you sign up?
Ask what happens to your plan and your support when you come off the medication, whether there is any post-medication guidance included, whether tapering is managed clinically, and what the cancellation terms are. Programs vary a lot here: some end contact when the prescription ends. Of the providers we have reviewed, HumeCare+ lists post-medication guidance as part of its plan, which is the sort of thing worth comparing before enrolling rather than after.
Related reading
Sources
- Aronne LJ, Sattar N, Horn DB, et al; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024 Jan 2;331(1):38-48. PMID: 38078870.
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. PMID: 35441470.
Disclosure: this article links to our review of HumeCare+, which contains an affiliate link. If you sign up through it we may earn a commission at no extra cost to you. That does not change what the trials above found. See our Editorial Policy.